A Phase 4 interventional study of Gelatin Sponge Sheet and Alvogyl in Pain, Procedural, sponsored by Karim ehab gerges. Status unknown. Per ClinicalTrials.gov, last updated 2019-02-08.
Sponsored by Karim ehab gerges · Phase 4, Interventional, and Supportive care
clinical comparison between alvogyl and gelatin sponge when used to protect the denuded area of the palatal donor site after free gingival graft in means of reducing pain and healing.
241 studies on the registry are indexed under Pain, Procedural; 64 are open to participants now.
This study's planned enrollment of 36 is below the median of 90 across 227 interventional studies indexed under Pain, Procedural.
Browse Pain, Procedural studies →This is the only study on the registry with Karim ehab gerges as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Gelatin Sponge Sheet is a heamostatic agent act as a mechanical barrier to protect the palatal donor site
Drug: Gelatin Sponge Sheet
alvogyl in a paste form with analgesic action to protect the palatal donor site and help to relief pain
Drug: Alvogyl
sheets act as a mechanical barrier used to protect the denuded area of the palatal donor site
Also known as: gel foam
paste form with analgesic action to protect the palatal donor site and help to relief pain
Also known as: Alveogyl
pain score
recorded by the pain trough a Visual Analogue scale score (between 0 and 10. 0: no pain, 1: minimal pain,10: severe pain)
Time frame: 2 weeks
healing
healing of the palatal mucosa using H2O2 Test this test is based on the principle that if the epithelium is discontinuous, then H2O2 diffuses into the CT, the enzyme catalase acts on H2O2to release water and oxygen. This is shown clinically by the production of bubbles on the wound. The area to be evaluated is then dried, and 3% H2O2 is sprinkled on the wound with a syringe, waiting for the appearance of bubbles, which will suggest that the surgical site is not completely epithelialized. Complete healing will be recorded as a dichotomous variable (yes/no).
Time frame: 4 weeks
bleeding
Questionaire, Binary (yes or no).
Time frame: 2 weeks
analgesic consumption
questionaure, Numerical, Amount of analgesics daily consumption
Time frame: 2 weeks
No study locations are listed for this record.
Start is estimated for Apr 2019; primary completion for Jun 2019, 2 months later.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Butyl aminobenzoate, eugenol, iodoform, spearmint oil drug combinations